A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of Topiramate in the Treatment of Obese, Type 2 Diabetic Patients on a Controlled Diet
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Obesity
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Enrollment
- 541
- Primary Endpoint
- The percent change in body weight and change in Hemoglobin A1c from enrollment to Week 60.
- Status
- Completed
- Last Updated
- 14 years ago
Overview
Brief Summary
The purpose of this study is to determine the efficacy and safety of topiramate compared with placebo in obese, Type 2 diabetic patients on a controlled diet.
Detailed Description
Topiramate is not approved for the treatment of obesity. This is a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of topiramate in obese, diet-controlled, type 2 diabetic patients. Patients are randomized to receive either topiramate or placebo. After a 5 week pre-enrollment phase followed by a 6 week run-in phase, patients in the topiramate group start an 8-week titration phase to reach the assigned dose of topiramate, either 96 or 192 mg daily. Treatment continues for 1 year. Assessments of effectiveness include percent change in body weight, hemoglobin type A1c \[HbA1c\] levels, Body Mass Index \[BMI\], the numbers and proportion of 5% and 10% weight loss responders, glucose tolerance, waist and hip circumferences, changes in the mass of left ventricle of the heart, blood pressures, and fasting lipid profiles. Safety evaluations, including incidence of adverse events, vital signs, clinical laboratory values, and electrocardiograms \[ECGs\], are monitored throughout the study. The study hypothesis is that topiramate, combined with controlled diet, will be effective in weight reduction and controlling blood sugar level and is well tolerated. During the initial 8 weeks, the oral doses of either a matching placebo or topiramate will be gradually increased to the target doses (96 milligrams\[mg\] or 192mg daily); the dose will be maintained for 1 year.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Body Mass Index \>= 27 and \< 50
- •Diagnosis of Type 2 diabetes according to either Swedish guideline or the American Diabetes Association (ADA) criteria
- •HbA1c \<10.5% at enrollment
- •No previous oral antidiabetic medication or insulin therapy
- •Stable body weight
- •Female patients must be postmenopausal for at least 1 year, surgically incapable of childbearing, practicing an acceptable method of contraception (requires negative pregnancy test)
Exclusion Criteria
- •Known contraindication or hypersensitivity to topiramate
- •Fasting plasma glucose (FPG) \>= 13.1 millimolesl/liter (240 milligrams/deciliter) at baseline, Visit 4 (Week 0)
- •HBA1c of \>10.5% at enrollment
- •History of severe recurrent hypoglycemic episodes prior to study entry
- •Use of any systemic corticosteroids within 30 days of enrollment
- •Diagnosed Type 1 diabetes
- •History of significant cardiovascular disease, uncontrolled thyroid disease, or kidney stones
Outcomes
Primary Outcomes
The percent change in body weight and change in Hemoglobin A1c from enrollment to Week 60.
Secondary Outcomes
- Change from enrollment or baseline to Week 60 in BMI, waist circumference, glucose tolerance, lipid profile; safety measures, such as adverse events, throughout study.